Momentum Stock Watch: Alnylam Pharmaceuticals (ALNY)
- Monday, January 11, 2021, 8:41
- Stock Market, Stock Research
- Add a comment
Company Profile: |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
Recent News: |
On January 8, 2021, the company announced positive top-line results from the phase III -HELIOS-A study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with polyneuropathy. |
|
Fundamental Analysis: |
Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency. |
Growth – Measures the growth of both the company’s income statement and cash flow. @@@@@ |
Profitability – Measures the historical price movement of the stock. @@@@@ |
Solvency – Measures the solvency of the company based on several ratios. @@@@@ |
Efficiency – Measures the strength and historic growth of a company’s return on invested capital. @@@@@ |
Conclusion: |
ALNY’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator, the RSI stands at around 66.86 with positive bias. We rate Alnylam Pharmaceuticals (ALNY) a STRONG BUY. |
About the Author
Write a Comment
Gravatars are small images that can show your personality. You can get your gravatar for free today!
You must be logged in to post a comment.